Amoéba Raises €6.67 Million and Defers Debt Balance to 2029
Amoéba has announced the successful completion of its capital increase through a private placement, raising €6.67 million from institutional investors. This move is part of a financial strengthening strategy to support the ramp-up of industrial operations and the commercial launch of its microbiological solutions.
Funding to Accelerate Industrial and Commercial Initiatives
The funds raised will enable Amoéba to accelerate the industrial ramp-up initiated through contracts with external CDMO providers. They will also finance the marketing and commercial support for developments undertaken by distribution partners and will support the development strategy in the cosmetics sector. The capital increase involves 8,897,973 new shares, representing 11.43% of the post-operation share capital. The settlement-delivery and the admission of the shares on Euronext Growth are scheduled for March 30, 2026.
Debt Refinancing Agreement Negotiated
Amoéba has negotiated a debt refinancing agreement with its reference shareholder Nice & Green, allowing the repayment of the bulk of its bond debt to be postponed to 2029. By combining the net proceeds from the capital increase, available liquidity, and the new repayment schedule, the Company estimates it can ensure its development and meet its financial commitments at least until December 31, 2026. Nice & Green's participation remains stable at 22.87% of the capital after the operation.
